跳至主要内容
临床试验/NCT01925287
NCT01925287已完成1 期

Novel Strategies for the Enhancement of the Potency of Nutraceuticals With Low Oral Bioavailability and Their Application in Novel Functional Foods for Optimum Protection of the Aging Brain

University of Hohenheim1 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2011年10月1日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
入组人数
23
试验地点
1
主要终点
Area under the plasma concentration versus time curve (AUC) of total demethoxycurcumin [nmol/L*h]

研究概览

简要总结

Background: The oral bioavailability of curcumin is low due to its limited intestinal uptake, rapid metabolism and excretion from the body. Considering its potent reported health-beneficial properties, researchers have tried to increase its bioavailability as a means to enhance its biological activities.

Objective: The aim of the project was to develop novel curcumin formulations with enhanced oral bioavailability and to study the safety of the formulations and potential sex-differences in humans.

Design: In this single-blind crossover study with three arms separated by ≥1-week washout periods, healthy subjects (13 women, 10 men) were provided standardized meals and took, in random order, a single oral dose of 500 mg curcumin as native powder, micronized powder, or liquid micelles. Blood and urine samples were collected in intervals for 24 h and total curcumin, demethoxycurcumin, and bis-demethoxycurcumin were quantified.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •healthy volunteers with routine blood chemistry values within the normal ranges

排除标准

  • •overweight (BMI >30 kg/m2)
  • •metabolic and endocrine diseases
  • •pregnancy
  • •lactation
  • •drug abuse
  • •use of dietary supplements or any form of medication (with the exception of oral contraceptives)
  • •frequent alcohol consumption (>20 g ethanol/d)
  • •adherence to a restrictive dietary regimen
  • •physical activity of more than 5 h/wk
  • •participation in a clinical trial within the past 3 months prior to recruitment
  • •known intolerance against curcuma

研究组 & 干预措施

Curcumin micelles

Experimental

500 mg curcumin incorporated into liquid micelles

干预措施: curcumin (Dietary Supplement)

Micronized curcumin powder

Experimental

500 mg curcumin as micronized powder

干预措施: curcumin (Dietary Supplement)

Native curcumin powder

Active Comparator

500 mg curcumin as native powder

干预措施: curcumin (Dietary Supplement)

结局指标

主要结局

Area under the plasma concentration versus time curve (AUC) of total demethoxycurcumin [nmol/L*h]

时间窗: 0, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 h post-dose

Total demethoxycurcumin was determined after deconjugation with beta-glucuronidase/sulphatase

Area under the plasma concentration versus time curve (AUC) of total bisdemethoxycurcumin [nmol/L*h]

时间窗: 0, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 h post-dose

Total bisdemethoxycurcumin was determined after deconjugation with beta-glucuronidase/sulphatase

Maximum plasma concentration (Cmax) of total demethoxycurcumin [nmol/L]

时间窗: 0, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 h post-dose

Total demethoxycurcumin was determined after deconjugation with beta-glucuronidase/sulphatase

Maximum plasma concentration (Cmax) of total bisdemethoxycurcumin [nmol/L]

时间窗: 0, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 h post-dose

Total bisdemethoxycurcumin was determined after deconjugation with beta-glucuronidase/sulphatase

Time to reach maximum plasma concentration (Tmax) of total curcumin [h]

时间窗: 0, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 h post-dose

Total curcumin was determined after deconjugation with beta-glucuronidase/sulphatase

Area under the plasma concentration versus time curve (AUC) of total curcumin [nmol/L*h]

时间窗: 0, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 h post-dose

Total curcumin was determined after deconjugation with beta-glucuronidase/sulphatase

Maximum plasma concentration (Cmax) of total curcumin [nmol/L]

时间窗: 0, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 h post-dose

Total curcumin was determined after deconjugation with beta-glucuronidase/sulphatase

Time to reach maximum plasma concentration (Tmax) of total demethoxycurcumin [h]

时间窗: 0, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 h post-dose

Total demethoxycurcumin was determined after deconjugation with beta-glucuronidase/sulphatase

Time to reach maximum plasma concentration (Tmax) of total bisdemethoxycurcumin [h]

时间窗: 0, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 h post-dose

Total bisdemethoxycurcumin was determined after deconjugation with beta-glucuronidase/sulphatase

次要结局

  • Glomerular filtration rate [mL/min](24 h post-dose)
  • Serum triacylglycerols [mg/dL](24 h post-dose)
  • Serum creatinine [mg/dL](24 h post-dose)
  • Serum aspartate transaminase activity [U/L](24 h post-dose)
  • Serum total cholesterol [mg/dL](24 h post-dose)
  • Serum LDL cholesterol [mg/dL](24 h post-dose)
  • Serum alanine transaminase activity [U/L](24 h post-dose)
  • Serum gamma-glutamyl transferase activity [U/L](24 h post-dose)
  • Serum bilirubin [mg/dL](24 h post-dose)
  • Serum uric acid [mg/dL](24 h post-dose)
  • Serum alkaline phosphatase activity [U/L](24 h post-dose)
  • Serum cystatin C [mg/L](24 h post-dose)
  • Serum HDL cholesterol [mg/dL](24 h post-dose)
  • Serum aspartate transaminase activity [U/L](Baseline)
  • Serum aspartate transaminase activity [U/L](4 h post-dose)
  • Serum alanine transaminase activity [U/L](Baseline)
  • Serum alanine transaminase activity [U/L](4 h post-dose)
  • Serum gamma-glutamyl transferase activity [U/L](Baseline)
  • Serum gamma-glutamyl transferase activity [U/L](4 h post-dose)
  • Serum alkaline phosphatase activity [U/L](Baseline)
  • Serum alkaline phosphatase activity [U/L](4 h post-dose)
  • Serum bilirubin [mg/dL](Baseline)
  • Serum bilirubin [mg/dL](4 h post-dose)
  • Serum uric acid [mg/dL](Baseline)
  • Serum uric acid [mg/dL](4 h post-dose)
  • Serum cystatin C [mg/L](Baseline)
  • Serum cystatin C [mg/L](4 h post-dose)
  • Glomerular filtration rate [mL/min](Baseline)
  • Glomerular filtration rate [mL/min](4 h post-dose)
  • Serum creatinine [mg/dL](Baseline)
  • Serum creatinine [mg/dL](4 h post-dose)
  • Serum total cholesterol [mg/dL](Baseline)
  • Serum total cholesterol [mg/dL](4 h post-dose)
  • Serum HDL cholesterol [mg/dL](Baseline)
  • Serum HDL cholesterol [mg/dL](4 h post-dose)
  • Serum LDL cholesterol [mg/dL](Baseline)
  • Serum LDL cholesterol [mg/dL](4 h post-dose)
  • Serum triacylglycerols [mg/dL](Baseline)
  • Serum triacylglycerols [mg/dL](4 h post-dose)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验